Tyra Biosciences (TYRA) Capital Expenditures (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Capital Expenditures data on file, last reported at $88000.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $88000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156000.0 (down 70.45% YoY) and the FY2025 annual result came in at $68000.0, down 89.76% from the prior year.
• Capital Expenditures improved to $88000.0 in Q1 2026, from $43000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $624000.0 in Q3 2024 to a low of -$210000.0 in Q2 2022.
• A 5-year average of $106000.0 and a median of $45000.0 in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures plunged 418.18% — and 2023, when it surged 6800.0%.
• Tracing TYRA's Capital Expenditures over 5 years: stood at -$9000.0 in 2022, then surged by 6800.0% to $603000.0 in 2023, then slumped by 99.0% to $6000.0 in 2024, then jumped by 616.67% to $43000.0 in 2025, then surged by 104.65% to $88000.0 in 2026.
• The last three Capital Expenditures figures came in at $88000.0 (Q1 2026), $43000.0 (Q4 2025), and -$20000.0 (Q3 2025), per Business Quant data.